Description
TACHYRA is indicated only for the treatment of the following documented, life-threatening recurrent ventricular arrhythmias when these have not responded to documented adequate doses of other available antiarrhythmics or when alternative agents could not be tolerated.
- Tachyarrhythmias associated with Wolff-Parkinson-White Syndrome.
Atrial flutter and fibrillation when other drugs cannot be used.
- All types of tachyarrhythmias of paroxysmal nature including: supraventricular, nodal and ventricular tachycardias, recurrent ventricular fibrillation: when other drugs cannot be used
